Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3810MR)

This product GTTS-WQ3810MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3810MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4175MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ15735MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ3014MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ3346MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ5042MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ11434MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ9910MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ8482MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HTI-1088
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW